Crossmark

Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer

Crossref DOI link: https://doi.org/10.1038/s41379-020-0544-x

Published Print: 2020-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Reisenbichler, Emily S. https://orcid.org/0000-0002-1570-6538
Han, Gang

Bellizzi, Andrew https://orcid.org/0000-0002-8264-6379
Bossuyt, Veerle

Brock, Jane

Cole, Kimberly

Fadare, Oluwole

Hameed, Omar

Hanley, Krisztina

Harrison, Beth T. https://orcid.org/0000-0002-8341-2961
Kuba, M. Gabriela

Ly, Amy

Miller, Dylan

Podoll, Mirna

Roden, Anja C.

Singh, Kamaljeet https://orcid.org/0000-0002-2506-5703
Sanders, Mary Ann

Wei, Shi

Wen, Hannah

Pelekanou, Vasiliki

Yaghoobi, Vesal

Ahmed, Fahad

Pusztai, Lajos

Rimm, David L. https://orcid.org/0000-0001-5820-4397
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA219647, R01CA219647)

Breast Cancer Research Foundation (BCRF-19-138)

U.S. Department of Health & Human Services | NIH | National Cancer Institute
License Information

Text and Data Mining valid from 2020-09-01

Text and Data Mining valid from 2020-09-01

Version of Record valid from 2023-01-11
More Information

This article is maintained by: Elsevier

Article Title: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer

Journal Title: Modern Pathology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1038/s41379-020-0544-x

Content Type: article

Copyright: © 2020 United States & Canadian Academy of Pathology.